

Forward-Looking Statements; Non-GAAP Information

Forward-Looking Statements This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements relating to Bausch Health Companies Inc.'s ("Bausch Health" or the "Company") future prospects and performance, financial guidance, research and development efforts and anticipated timing or results thereof, proposed plan to separate its eye health business, including the timing thereof, management of its balance sheet, generation of cash, ability to launch and commercialize new products, including the timing of regulatory processes with respect to the Company's product pipeline, ability to enforce and defend its XIFAXAN® intellectual property rights, ability to execute its growth strategies generally, and other corporate and strategic transactions. Forward-looking statements may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and positive and negative variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken, or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements, including the full-year guidance, are based upon the current expectations and beliefs of management. The Company's 2025 financial outlook and full-year guidance are included to provide further information about management's expectations about the Company's future business operations, activities and results and may not be appropriate for other purposes.

These forward-looking statements are subject to certain factors, risks and uncertainties that could cause actual results to differ materially from those described in these forward-looking statements. These factors, risks and uncertainties include, but are not limited to the following: the impact of current market and economic conditions in one or more of the Company's markets; the impact of inflation and other macroeconomic factors on the Company's business and operations; the ability to complete the separation of Bausch + Lomb, including the timing and structure thereof, and to achieve the expected benefits thereof, and other risks and uncertainties relating to such separation, including actual and potential litigation related thereto; uncertainty of commercial success for new and existing products; challenges to patents; challenges to the Company's ability to enforce and defend against challenges to its patents; the impact of patent expirations and the ability of the company to successfully execute strategic plans; compliance with legal and regulatory requirements; our substantial debt and current and future debt service obligations; the impact of potential imposition of and adverse changes to duties, tariffs and other trade protection measures (including any retaliations to such measures); and other factors, risks and uncertainties discussed in the Company's most recent annual and quarterly reports and detailed from time to time in the Company's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors, risks and uncertainties are incorporated herein by reference.

Additional information regarding certain of these material factors and assumptions may be found in the Company's filings described above. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable in the circumstances, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this presentation or to reflect actual outcomes, unless required by law.

The guidance in this presentation is only effective as of the date given and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. Distribution or reference of this presentation following the date of this presentation does not constitute the Company re-affirming guidance.

Non-GAAP Information To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses certain non-GAAP financial measures and non-GAAP ratios to provide supplemental information to readers. Management uses these non-GAAP measures and ratios as key metrics in the evaluation of the Company's performance and the consolidated financial results and, in part, in the determination of cash bonuses for its executive officers. The Company believes these non-GAAP measures and ratios are useful to investors in their assessment of our operating performance. In addition, these non-GAAP measures and ratios address questions the Company routinely receives from analysts and investors and, in order to assure that all investors have access to similar data, the Company has determined that it is appropriate to make this data available to all investors.

However, these measures and ratios are not prepared in accordance with GAAP nor do they have any standardized meaning under GAAP. In addition, other companies may use similarly titled non-GAAP financial measures and ratios that are calculated differently from the way we calculate such measures and ratios. Accordingly, our non-GAAP financial measures and ratios may not be comparable to such similarly titled non-GAAP financial measures and ratios used by other companies. We caution investors not to place undue reliance on such non-GAAP measures and ratios, but instead to consider them with the most directly comparable GAAP measures and ratios. Non-GAAP financial measures and ratios have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

The reconciliations of these historic non-GAAP financial measures and ratios to the most directly comparable financial measures and ratios calculated and presented in accordance with GAAP are shown in the Appendix hereto. However, as indicated above, for guidance purposes, the Company does not provide reconciliations of projected Adjusted EBITDA (non-GAAP) to projected GAAP Net income (loss), projected Adjusted Cash Flow from Operations (non-GAAP) to projected GAAP Cash Generated from Operations, projected Adjusted Gross Margin (non-GAAP) to projected GAAP Gross Margin, projected Adjusted SG&A Expense to projected GAAP SG&A Expense, projected Adjusted Tax Rate to projected GAAP tax rate and projected organic growth (non-GAAP) to projected revenue growth, in each case due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. Many of the adjustments and exclusions used to calculate the projected non-GAAP measures may vary significantly based on actual events, so the Company is not able to forecast on a GAAP basis with reasonable certainty all adjustments needed in order to provide a GAAP calculation of these projected amounts. The amounts of these adjustments may be material and, therefore, could result in the GAAP amount being materially different from (including materially less than) the projected non-GAAP measures.

For further information on non-GAAP financial measures and ratios, please see the Non-GAAP Appendix,

Agenda



Business Update



4Q & FY 2024 Financial Results



2025 Guidance



Closing Remarks, Q&A





Bausch Health (excl. B+L) Financial Highlights

Revenue

- 4Q24 Revenue grew 4% and 7% on a reported and organic¹ basis, respectively
- FY24 Revenue grew 5% and 6% on a reported and organic¹ basis, respectively
- All segments grew revenue in FY24

Adjusted EBITDA¹

- 4Q24 Adj. EBITDA¹ increased by 7%, while FY24 grew 8%
- All segments grew segment profit² in FY24

Cash Flow

- 4Q24 Adjusted Operating Cash Flow¹ of \$567M, up ~104% vs. 4Q23
- FY24 Adjusted Operating Cash Flow¹ of \$1.3 Billion
- Net Debt down \$518M in 4Q24, and \$990M for FY24

Value Creation

- Relentlessly focused on enhancing the value of BHC's operational assets
- Actively exploring all avenues to unlock the full value of our B+L equity stake
- Committed to optimizing our capital structure

CONSISTENT STRONG EXECUTION IN 2024 CREATES MOMENTUM INTO 2025

^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

^{2.} Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation costs, Other (income) expense, net, and other corporate allocations are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.

Strategic Priorities

Enriching lives through our relentless drive to deliver better health outcomes



People

Principled leaders, creative thinkers, problem solvers, and result seekers



Growth

Expanding growth across segments and geographies



Innovation

Inspiring innovation and technological advancement



Efficiency

Driving operational efficiency and execution



Unlocking Value

Working all levers

Strategic Priorities

Enriching lives through our relentless drive to deliver better health outcomes



People

 Added key personnel to executive leadership team



JJ Charhon
Chief Financial Officer



Aimee Lenar

Executive Vice
President, US Pharma



Jonathan Sadeh, M.D., M.Sc. Executive Vice President, CMO and Head of R&D

HCBHCB

Strategic Priorities¹

Enriching lives through our relentless drive to deliver better health outcomes





Growth

- In 2024, Solta grew 27% while Xifaxan® grew 10% with momentum
- Durable International segment grew mid-single digits by geography with Canada and EMEA being the strongest contributors



Innovation

- Aesthetics offering Thermage® FLX approved as medical device in China
- Al toolkit to assist our sales teams for Xifaxan®, we believe a driver of performance in 2024
- RED-C program for the prevention and delay of the first episode of HE on track with 2 global phase 3 trials; top-line expected early 2026

Strategic Priorities¹

Enriching lives through our relentless drive to deliver better health outcomes



Efficiency

- Strong supply chain expertise, nimble in meeting unexpected supply needs
- Solid execution on CABTREO[®] launch through 2024



Unlocking Value

 Fully committed to utilizing all levers at our disposal in a methodical and deliberate manner

1. See Slide 2 for further information on forward-looking statements.

Bausch Health (excl. B+L) Delivers

- Xifaxan® volume growth in 4Q24 remains broad based, with ~5% retail script growth and ~18% non-retail extended unit growth
- Solta grew 34% in 4Q24, again led by Asia Pacific region, with Korea and China as primary drivers
- Durable International business delivers steady growth off a diverse platform
 - Canada achieved double-digit growth in promoted brands
 - EMEA grew mid-single digits
- Investments in new partnerships in late 4Q24 and early 2025, leveraging partners' portfolio development with BHC's robust footprint in Latin America and Canada
- Optimizing Diversified segment's portfolio which remains strategic

Strong finish to a great year carrying momentum into 2025

16%

Xifaxan[®] revenue growth in fourth quarter with solid Rx² growth

4th

Consecutive quarter of Revenue growth

27%

Solta Revenue growth in 2024

8th

Consecutive quarter of organic¹ growth for EMEA region


7th

Consecutive quarter of Revenue and Adj. EBITDA¹ growth

2. Rx = Prescription

BAUSCH Health

This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.



4Q 2024 GAAP Financial Results

Amounts in millions USD, except EPS amounts

	Three Months Ended		Favorable (Unfavorable)
	December 31, 2024	December 31, 2023	Reported
Revenues	\$2,559	\$2,408	6%
GAAP Gross Profit	\$1,550	\$1,421	9%
GAAP Gross Margin	60.6%	59.0%	160 bps
Selling, A&P	\$582	\$550	(6%)
GAAP G&A	\$238	\$216	(10%)
R&D	\$163	\$152	(7%)
GAAP Total Operating Expense	\$992	\$1,059	6%
GAAP Operating Income	\$558	\$362	54%
GAAP Net Income (Loss) Attributable to Bausch Health Companies Inc.	\$93	(\$39)	338%
GAAP Earnings (Loss) per Share Attributable to Bausch Health Companies Inc.	\$0.25	(\$0.11)	
GAAP Cash Flow from Operations	\$601	\$390	54%

FY 2024 GAAP Financial Results

Amounts in millions USD, except EPS amounts

	Twelve Mo	Favorable (Unfavorable)	
	December 31, 2024	December 31, 2023	Reported
Revenues	\$9,625	\$8,757	10%
GAAP Gross Profit	\$5,737	\$5,067	13%
GAAP Gross Margin	59.6%	57.9%	170 bps
Selling, A&P	\$2,299	\$2,018	(14%)
GAAP G&A	\$997	\$899	(11%)
R&D	\$616	\$604	(2%)
GAAP Total Operating Expense	\$4,191	\$4,104	(2%)
GAAP Operating Income	\$1,546	\$963	61%
GAAP Net Loss Attributable to Bausch Health Companies Inc.	(\$46)	(\$592)	92%
GAAP Loss per Share Attributable to Bausch Health Companies Inc.	(\$0.13)	(\$1.62)	-
GAAP Cash Flow from Operations	\$1,597	\$1,032	55%

4Q 2024 Non-GAAP¹ Financial Results

Amounto in milliono LICD				
Amounts in millions USD	Three Months Ended		Favorable (Unfavorable)	
	December 31, 2024	December 31, 2023	Reported	Constant Currency ¹
Revenues	\$2,559	\$2,408	6%	7%
Adj. Gross Profit ¹	\$1,853	\$1,724	7%	9%
Adj. Gross Margin ¹	72.4%	71.6%	80 bps	-
Selling, A&P (Same as reported)	\$582	\$550	(6%)	(7%)
Adj. G&A ¹	\$213	\$190	(12%)	(14%)
Adj. R&D ¹	\$163	\$151	(8%)	(9%)
Total Adj. Operating Expense ¹	\$958	\$891	(8%)	(9%)
Adj. EBITA¹	\$895	\$833	7%	8%
Adj. EBITDA Attributable to Bausch Health Companies Inc. ¹	\$935	\$869	8%	9%
Adj. Net Income Attributable to Bausch Health Companies Inc. ¹	\$430	\$406	6%	-
Diluted Shares Outstanding ²	373.5M	368.2M	-	-
Adj. Cash Flows from Operations ^{1,3}	\$601	\$305	97%	-

^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

^{2.} For the three months ended December 31, 2023, this figure includes the dilutive impact of options and restricted stock units of approximately 2,082,000 common shares which are excluded when calculating GAAP diluted loss per share because the effect of including these amounts in the calculation would have been anti-dilutive.

^{3.} Excludes legacy legal settlements (net of insurance recoveries), separation payments, separation-related payments, business transformation costs, and includes interest payments charged against premium.

FY 2024 Non-GAAP¹ Financial Results

Amounts in millions USD				
	Twelve Months Ended		Favorable (Unfavorable)	
	December 31, 2024	December 31, 2023	Reported	Constant Currency ¹
Revenues	\$9,625	\$8,757	10%	11%
Adj. Gross Profit ¹	\$6,925	\$6,221	11%	12%
Adj. Gross Margin ¹	71.9%	71.0%	90 bps	-
Selling, A&P (Same as reported)	\$2,299	\$2,018	(14%)	(15%)
Adj. G&A ¹	\$880	\$770	(14%)	(15%)
Adj. R&D¹	\$615	\$602	(2%)	(2%)
Total Adj. Operating Expense ¹	\$3,812	\$3,390	(12%)	(13%)
Adj. EBITA ¹	\$3,113	\$2,831	10%	11%
Adj. EBITDA Attributable to Bausch Health Companies Inc. ¹	\$3,307	\$3,014	10%	10%
Adj. Net Income Attributable to Bausch Health Companies Inc. ¹	\$1,394	\$1,274	9%	-
Diluted Shares Outstanding ²	371.2M	367.7M	-	-
Adj. Cash Flows from Operations ^{1,3}	\$1,572	\$763	106%	-


^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

^{2.} For the twelve months ended December 31, 2024 and 2023, this figure includes the dilutive impact of options and restricted stock units of approximately 3,142,000 and 2,719,000 common shares, respectively, which are excluded when calculating GAAP diluted loss per share because the effect of including this impact in this calculation would have been anti-dilutive.


^{3.} Excludes legacy legal settlements (net of insurance recoveries), separation payments, separation-related payments, business transformation costs, and includes interest payments charged against premium.

4Q 2024 Revenue

Amounts in millions USD










STRONG FOURTH QUARTER ON A REPORTED AND ORGANIC BASIS

FY 2024 Revenue

Amounts in millions USD









SOLID GLOBAL FOUNDATION IN 2024, POSITIONING US WELL FOR 2025

4Q24 & FY24 Adjusted EBITDA^{1,2}

Amounts in millions USD







HIGH SINGLE-DIGIT ADJUSTED EBITDA1 GROWTH IN FOURTH QUARTER AND FULL YEAR 2024

- 1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
- 2. Adjusted EBITDA includes Adjusted EBITDA attributable to noncontrolling interests. For Bausch Health Companies Inc., this amounted to \$37 million and \$118 million for the three and twelve months ended December 31, 2024, which includes \$1 million and \$12 million, respectively related to B+L.

4Q24 & FY24 Adjusted Cash Flow from Operations¹

Amounts in millions USD





CONTINUED STRONG FREE CASH FLOW GENERATION IN 2024

Note: May not sum to total due to rounding

Salix Segment – 4Q 2024

Amounts in millions USD





Highlights

- Xifaxan[®] NRx³ up 5%
- Strong Xifaxan[®] non-retail growth
- Trulance[®] healthy 4Q24 growth
- Relistor® flat for FY 2024

XIFAXAN® DRIVES GROWTH FOR SALIX

- 1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
- TRx = total prescriptions. Source: IQVIA.
- NRx = new prescriptions. Source: IQVIA.

International Segment – 4Q 2024

Amounts in millions USD



Region Reported Organic¹ Canada 9% 16% EMEA 4% 5% LATAM (25%) (14%) Totals: Reported: (4%) Organic¹: 1%

Highlights


- Canada Strong Wellbutrin demand, promoted products +13%
- EMEA Good growth in Poland and other markets²
- LATAM FX and timing of government purchases

CONTINUED ORGANIC GROWTH FOR INTERNATIONAL SEGMENT

- 1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios
- 2. Organic revenue growth, which is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios

Solta Medical Segment – 4Q 2024

Amounts in millions USD





Highlights

- Global growth driven by higher volumes
- China +49%², fueled by Thermage[®] FLX
- Korea +165%² from consumer demand


Reported: 34% Organic¹: 35%

ANOTHER STRONG QUARTER FOR SOLTA

- 1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
- 2. Organic revenue growth, which is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

Diversified Segment – 4Q 2024

Amounts in millions USD



Revenue vs. 4Q23 **Business** Reported Organic¹ Neurology 1% 1% Dermatology (13%)(4%)(17%)(17%)Dentistry Generics (68%)(70%)**Totals: Reported:** (12%) Organic¹: (11%)

Highlights

- Neurology Benefit in 4Q23 from competitor supply disruptions
- Dermatology CABTREO[®] launch offset by discontinuations & pricing
- Generics Optimizing portfolio in a strategic business


NEUROLOGY STRATEGY DRIVING PERFORMANCE


Bausch Health (excl. B+L) Revenue – FY 2024

Amounts in millions USD










REVENUE GROWTH ACROSS ALL SEGMENTS

Bausch + Lomb – 4Q 2024

Amounts in millions USD










CONTINUED GROWTH ACROSS ALL BUSINESSES

Bausch + Lomb - FY 2024

Amounts in millions USD









CONTINUED GROWTH ACROSS ALL BUSINESSES

Bausch Health (excl. B+L) Revenue & Segment Profit¹ – 4Q 2024

Amounts in millions USD

R	BHCB	
	4Q 24	vs. 4Q 23
Salix	\$634	9%
International	\$279	(4%)
Diversified	\$228	(12%)
Solta	\$138	34%
Total	\$1,279	4%

Segment Profit ¹			
BHCBHCB	4Q 24	vs. 4Q 23	
Salix	\$460	10%	
International	\$98	(1%)	
Diversified	\$157	(7%)	
Solta	\$73	55%	
Total	\$788	7%	

Hig	hl	ig	hts
-----	----	----	-----


- → Double-digit segment profit growth
- → Effective cost management
- → Operating leverage from net pricing / cost management
- → Operating leverage on revenue growth

OPERATING LEVERAGE ACROSS PORTFOLIO

^{1.} Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation costs, Other (income) expense, net, and other corporate allocations are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.

Bausch Health (excl. B+L) Debt

As of 4Q 2024, amounts in millions USD



^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

^{2.} Debt values are shown at principal value. Cash balance consists of cash and cash equivalents and restricted cash. Net debt is net of cash and cash equivalents and restricted cash. Amounts shown may not foot due to rounding.



Full Year 2025 Guidance^{1,2}

All amounts are approximate, in billions USD

	2025 Guidance ^{1,2}
Bausch Health Companies	
Net Revenue	\$9.900 - \$10.150
Adjusted EBITDA ¹	\$3.525 - \$3.675
Bausch + Lomb	
Net Revenue	\$4.950 - \$5.050
Adjusted EBITDA ¹	\$0.900 - \$0.950
Bausch Health Companies (Excl. B+L)	
Net Revenue	\$4.950 - \$5.100
Reported Revenue Growth	2% - 6%
Adjusted EBITDA ¹	\$2.625 - \$2.725
Adjusted Operating Cash Flow ^{1,3}	\$0.975 - \$1.025

STRENGTH OF OUR
PROFIT AND CASH FLOW
PERFORMANCE IN 2024
GIVE US CONFIDENCE IN
OUR OUTLOOK FOR THE
FULL YEAR 2025

^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

^{2.} See Slide 2 for further information on forward-looking statements.

^{3.} Excludes legacy legal settlements (net of insurance recoveries), separation payments, separation-related payments, business transformation costs and interest payments charged against premium.

Bausch Health (excl. B+L) 2025 Guidance^{1,4} Summary

All amounts are approximate, in millions USD	FY 2024 Actuals	FY 2025 Guidance ^{1,2,4}	
Net Revenue	5%	2% - 6%	=
Adj. Gross Margin ¹	81%	~81%	=
Adj. EBITDA ¹	8%	3% - 7%	-
Adj. Cash Flow from Operations ^{1,3}	\$1,308	\$975 - \$1,025	-
Organic Growth ¹	6%	4% - 7%	=

2025 GUIDANCE CONTINUES STRONG MOMENTUM FROM 2024

- 1. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
- 2. Based on FX rates (local currency per US dollar) including MXN 21.14, PLN 4.06, CNY 7.17, CAD 1.42, KRW 1,433. FX impact may change based on fluctuations in currency rates in future periods.
- 3. Excludes legacy legal settlements (net of insurance recoveries), separation payments, separation-related payments, business transformation costs and interest payments charged against premium.
- 4. See Slide 2 for further information on forward-looking statements.

Value Creation Framework¹



Increase Bausch Health Enterprise Value



Maximize the Value of Our BLCO Asset



Optimize Our Capital Structure

WORKING ALL LEVERS OF VALUE CREATION

1. See Slide 2 for further information on forward-looking statements.

©2025 Bausch Health and/or one of its affiliates.

Strategic Priorities¹

Enriching lives through our relentless drive to deliver better health outcomes

- 1. See Slide 2 for further information on forward-looking statements.
- This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.



People

Drive results-oriented culture of accountability



Growth

Deliver on Revenue, Adjusted EBITDA² and Adjusted Operating Cash Flow² Guidance



Innovation

Intensify focus and operating rigor behind R&D and business development



Efficiency

Execute with operational excellence and a costfocused mindset across the enterprise



Unlocking Value

Continue to evaluate strategic alternatives; achieving full separation of B+L remains a priority

Key Takeaways



Achieved Seventh
Consecutive Quarter
of Growth



Exceeded/High-End of 2024 Guidance w/Strong Cash Flow



Carrying Momentum Into 2025¹



Delivering
On Our
Commitments

OUR EXECUTION PROVIDES A STRONG FOUNDATION FOR CONTINUED MOMENTUM ACROSS OUR BUSINESS

1. See Slide 2 for further information on forward-looking statements.

©2025 Bausch Health and/or one of its affiliates.

Appendix

On Track With Our Key R&D Initiatives¹

Key Clinical Programs	Phase 1	Phase 2	Phase 3	Approval/Launch	Notes
DERMATOLOGY					
CABTREO® First triple combination product for the treatment of acne vulgaris					First and only FDA-approved fixed-dose, triple-combination topical treatment for acne successfully launched in the U.S. in 1Q 2024 Launched in Canada in October 2024
SALIX					
RED-C Prevention and delay of first episode of hepatic encephalopathy					Both RED-C global Phase 3 trials currently in treatment phase On track for top-line Phase 3 results by early 2026
Amiselimod (S1P modulator) Treatment for mild to moderate ulcerative colitis					Submitted draft protocols for Phase 3 trial addressing moderate- to severe- Ulcerative Colitis patients Met with all planned major regulatory bodies (FDA, EMA (EU), and PMDA (Japan) by year-end 2024 All regulatory feedback under review
SOLTA MEDICAL					
Thermage® FLX Radio-frequency technology to help tighten and improve the smoothness and texture of skin's surface					Received National Medical Products Administration (NMPA) approval in China in January 2024, followed by a successful launch Submitted for approval in Canada during 4Q 2024
Clear + Brilliant® Touch Fractionated laser device for skin rejuvenation					Ex-U.S., approvals by the end of 2024 have been received for Australia, New Zealand, Philippines, Thailand, Taiwan, Malaysia and Singapore Submitted for approval in Canada during 4Q 2024; Awaiting European regulatory response to submission
Next Generation Fraxel® Fractionated laser device for skin resurfacing				,	Received FDA clearance in August 2024 U.S. commercial launch expected in 2025

^{1.} Progress timelines are for illustrative purposes only; See Slide 2 for further information on forward-looking statements.

Balance Sheet Summary

Amounts in millions USD		As of December 31,	
	2024	2023	2022
Cash and cash equivalents ¹	\$1,201	\$962	\$591
Revolving Credit Facilities	\$110 ⁵	\$275 ⁵	\$470
AR Credit Facility	\$300	\$350	\$-
Senior Secured Debt (principal amount) ²	\$15,233	\$15,203	\$13,300
Senior Unsecured Debt (principal amount) ²	\$5,247	\$5,803	\$5,810
Total Consolidated Debt (principal amount) ²	\$20,480	\$21,006	\$19,110
Total Consolidated Debt (net of premiums and discounts)	\$21,616	\$22,388	\$20,766
Net Consolidated Debt (principal amount) ³	\$19,299	\$20,059	\$18,546
TTM GAAP Net Loss	(\$72)	(\$611)	(\$212)
TTM Adj. EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP) ⁴	\$3,307	\$3,014	\$3,022


WE CONTINUE TO PRIORITIZE LIQUIDITY MANAGEMENT AND THE DE-LEVERING OF OUR BALANCE SHEET

- 1. Cash and cash equivalents includes restricted cash of \$20M, \$15M and \$27M as of 12/31/24, 12/31/23 and 12/31/22, respectively.
- 2. Debt balances shown at principal value. Senior secured debt figure is inclusive of revolving credit facilities drawn (if any), AR Credit Facility and \$1,900M of secured debt for Bausch + Lomb's acquisition of Xiidra in 3Q 2023.
- 3. Net consolidated debt is net of unrestricted cash and cash equivalents.
- 4. This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.
- 5. No outstanding borrowings under Bausch Health (excl. B+L) revolving credit facility at December 31, 2024

Unconsolidated

Bausch Health (excl. B+L) Debt Maturity Profile¹

As of 4Q 2024, amounts in millions USD



Bausch Health (excl. B+L) Debt

Total: \$15.6B¹

Restricted: \$14.3B Unrestricted: \$1.3B²

Reduced debt by:

~\$30M

in 4Q 2024

Reduced debt, net of cash, by:

~\$520M

in 4Q 2024

^{1.} Debt values are shown at principal value. Does not include ~\$3.3B of Bausch + Lomb term loans, \$110M of Bausch + Lomb revolving credit facility, and ~\$1.4B of Bausch + Lomb senior secured notes.

^{2.} Consists of \$1B non-recourse debt issued by a wholly-owned unrestricted subsidiary, 1375209 B.C. Ltd., that owns ~38.3% of the issued and outstanding shares of Bausch + Lomb, and \$300M outstanding under AR credit facility.

4Q & FY 2024 Revenue Performance

	4Q24	4Q23	Reported	Organic ¹	FY24	FY23	Reported	Organic ¹
Salix	\$634	\$583	9%	12%	\$2,333	\$2,250	4%	5%
International	\$279	\$290	(4%)	1%	\$1,111	\$1,071	4%	4%
Solta Medical	\$138	\$103	34%	35%	\$440	\$347	27%	29%
Neurology	\$142	\$141	1%	1%	\$543	\$494	10%	10%
Dermatology	\$53	\$61	(13%)	(4%)	\$238	\$226	5%	12%
Generics	\$9	\$28	(68%)	(70%)	\$74	\$120	(38%)	(34%)
Dentistry	\$24	\$29	(17%)	(17%)	\$95	\$103	(8%)	(8%)
Diversified	\$228	\$259	(12%)	(11%)	\$950	\$943	1%	3%
Bausch Health (excl. B+L)	\$1,279	\$1,235	4%	7%	\$4,834	\$4,611	5%	6%
Vision Care	\$723	\$662	9%	11%	\$2,739	\$2,543	8%	9%
Surgical	\$231	\$204	13%	12%	\$843	\$767	10%	10%
Pharmaceuticals	\$326	\$307	6%	7%	\$1,209	\$836	45%	15%
Bausch + Lomb	\$1,280	\$1,173	9%	10%	\$4,791	\$4,146	16%	10%
Total Bausch Health	\$2,559	\$2,408	6%	9%	\$9,625	\$8,757	10%	8%

^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios

Unconsolidated

Inventory in Select U.S. Businesses (QTD)¹

			Months	on Hand		
Business Units	As of Sep 30, 2023	As of Dec 31, 2023	Change 4Q23	As of Sep 30, 2024	As of Dec 31, 2024	Change 4Q24
Dermatology	1.17	1.04	(0.13)	1.14	1.08	(0.06)
Neurology	1.18	1.18	0.00	1.12	1.02	(0.10)
Salix	1.25	1.20	(0.05)	1.10	1.09	(0.01)

^{1.} U.S. wholesale inventory

Unconsolidated

Inventory in Select U.S. Businesses (FY24)¹

			Months	on Hand		
Business Units	As of Dec 31, 2022	As of Dec 31, 2023	Change YTD23	As of Dec 31, 2023	As of Dec 31, 2024	Change YTD24
Dermatology	1.07	1.04	(0.03)	1.04	1.08	0.04
Neurology	1.17	1.18	0.01	1.18	1.02	(0.16)
Salix	1.02	1.20	0.18	1.20	1.09	(0.11)

^{1.} U.S. wholesale inventory

Other Financial Information

Amounts in millions 000	Three Mor	nths Ended	Favorable (Unfavorable)	Twelve Mo	onths Ended	Favorable (Unfavorable)
	December 31, 2024	December 31, 2023	Reported	Constant Currency ¹	December 31, 2024	December 31, 2023	Reported	Constant Currency ¹
Cash Interest Paid ²	\$373	\$450	17%	17%	\$1,674	\$1,533	(9%)	(9%)
Net Interest Expense (GAAP)	\$328	\$356	8%	8%	\$1,355	\$1,302	(4%)	(4%)
Non-cash adjustments								
Depreciation	\$48	\$47	(2%)	(4%)	\$190	\$187	(2%)	(2%)
Non-cash share-based Comp	\$43	\$29	(48%)	(48%)	\$150	\$132	(14%)	(14%)
Additional cash items								
Contingent Consideration	\$10	\$23	-	-	\$37	\$45	-	-
Milestones/License Agreements and Other Intangibles	\$1	\$46	-	-	\$21	\$57	-	-
Restructuring and Other	\$21	\$14	-	-	\$86	\$47	-	-
Capital Expenditures	\$106	\$98	-	-	\$337	\$215	-	-
Adj. Tax Rate ¹	18.6%	10.8%	-	-	17.1%	13.0%	-	-
GAAP Tax Rate	53.3%	524.9%	-	-	143.2%	56.6%	-	-

^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

^{2.} Cash interest paid includes payments recorded against debt premiums.

Non-GAAP Adjustments EPS Impact

Amounts in millions USD, except EPS impact		Three Mo	nths Ended					
	December	31, 2024	December	· 31, 2023	December	31, 2024	December	31, 2023
	Income (Expense)	EPS Impact ²						
Net Income (Loss)	\$98	\$0.26	(\$47)	(\$0.13)	(\$72)	(\$0.20)	(\$611)	(\$1.67)
Non-GAAP adjustments:1								
Amortization of intangible assets	259	0.69	282	0.77	1,077	2.90	1,077	2.93
Goodwill impairments	-	-	91	0.25	-	-	493	1.34
Asset impairments	23	0.06	-	-	29	0.08	54	0.15
Restructuring, integration and transformation costs	16	0.04	31	0.08	66	0.18	116	0.32
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	18	0.05	45	0.12	101	0.27	122	0.33
Gain on extinguishment of debt	-	-	(1)	-	(23)	(0.06)	(1)	-
IT infrastructure investment	8	0.02	9	0.02	35	0.09	31	0.08
Separation costs and separation-related costs	8	0.02	6	0.02	24	0.06	26	0.07
Legal and other professional fees	-	-	3	0.01	25	0.07	20	0.05
(Gain) loss on sale of assets, net	-	-	1	-	(10)	(0.03)	(3)	(0.01)
Litigation and other matters, net of insurance recoveries	5	0.01	2	0.01	220	0.59	(53)	(0.14)
Other	7	0.02	4	0.01	19	0.05	13	0.04
Tax effect of non-GAAP¹ adjustments	9	0.02	(11)	(0.03)	(57)	(0.15)	25	0.07
EPS difference between basic and diluted shares	-	0.02	-	-	-	0.02	-	-
Adjusted net income (non-GAAP)¹	451	-	415	-	1,434	-	1,309	-
Adjusted net income attributable to noncontrolling interest (non-GAAP) ¹	(21)	(0.06)	(9)	(0.02)	(40)	(0.11)	(35)	(0.10)
Adjusted net income attributable to Bausch Health Companies Inc. (non-GAAP)¹	\$430	-	\$406	-	\$1,394	-	\$1,274	-

^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

^{2.} Includes 2,082,000 diluted shares for the three months ended December 31, 2023, and 3,142,000 and 2,719,000 diluted shares for the twelve months ended December 31, 2024 and 2023, respectively, as the inclusion of these shares would be anti dilutive.

4Q24 Reconciliation of Reported Operating Income to Adjusted EBITA (Non-GAAP)¹

Amounts in millions USD														
				4Q24							4Q23			
	Gross Profit	Gross Margin	Selling & Advertising	G&A	R&D Expense	Operating Expense	Operating Income	Gross Profit	Gross Margin	Selling & Advertising	G&A	R&D Expense	Operating Expense	Operating Income
GAAP Operating Income	\$1,550	60.6%	\$582	\$238	\$163	\$992	\$558	\$1,421	59.0%	\$550	\$216	\$152	\$1,059	\$362
Amortization of intangible assets	259	10.1%	-	-	-	-	259	282	11.7%	-	-	-	-	282
Goodwill impairments	-	-	-	-	-	-	-	-	-	-	-	-	(91)	91
Asset impairments	23	0.9%	-	-	-	-	23	-	-	-	-	-	-	-
Restructuring, integration and transformation costs	-	-	-	(10)	-	(16)	16	-	-	-	(10)	-	(31)	31
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	21	0.8%	-	-	-	3	18	21	0.9%	-	-	-	(24)	45
IT infrastructure investment	-	-	-	(8)	-	(8)	8	-	-	-	(9)	-	(9)	9
Separation costs and separation-related costs	-	-	-	(7)	-	(8)	8	-	-	-	(4)	(1)	(6)	6
Legal and other professional fees	-	-	-	-	-	-	-	-	-	-	(3)	-	(3)	3
(Gain) loss on sale of assets, net	-	-	-	-	-	-	-	-	-	-	-	-	(1)	1
Litigation and other matters	-	-	-	-	-	(5)	5	-	-	-	-	-	(2)	2
Other	-	-	-	-	-	-	-	-	-	-	-	-	(1)	1
Adjusted EBITA (Non-GAAP) ¹	\$1,853	72.4%	\$582	\$213	\$163	\$958	\$895	\$1,724	71.6%	\$550	\$190	\$151	\$891	\$833

^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

Unconsolidated

FY24 Reconciliation of Reported Operating Income to Adjusted EBITA (Non-GAAP)¹

Amounts in millions USD														
				FY24							FY23			
	Gross Profit	Gross Margin	Selling & Advertising	G&A	R&D Expense	Operating Expense	Operating Income	Gross Profit	Gross Margin	Selling & Advertising	G&A	R&D Expense	Operating Expense	Operating Income
GAAP Operating Income	\$5,737	59.6%	\$2,299	\$997	\$616	\$4,191	\$1,546	\$5,067	57.9%	\$2,018	\$899	\$604	\$4,104	\$963
Amortization of intangible assets	1,077	11.2%	-	-	-	-	1,077	1,077	12.3%	-	-	-	-	1,077
Goodwill impairments	-	-	-	-	-	-	-	-	-	-	-	-	(493)	493
Asset impairments	29	0.3%	-	-	-	-	29	54	0.6%	-	-	-	-	54
Restructuring, integration and transformation costs	-	-	-	(37)	-	(66)	66	-	-	-	(58)	-	(116)	116
Acquisition-related costs and adjustments (excluding amortization of intangible assets)	82	0.9%	-	-	-	(19)	101	23	0.3%	-	-	-	(83)	106
IT infrastructure investment	-	-	-	(35)	-	(35)	35	-	-	-	(31)	-	(31)	31
Separation costs and separation-related costs	-	-	-	(20)	(1)	(24)	24	-	-	-	(20)	(2)	(26)	26
Legal and other professional fees	-	-	-	(25)	-	(25)	25	-	-	-	(20)	-	(20)	20
(Gain) loss on sale of assets, net	-	-	-	-	-	10	(10)	-	-	-	-	-	3	(3)
Litigation and other matters	-	-	-	-	-	(220)	220	-	-	-	-	-	53	(53)
Other	-	-	-	-	-	-	-	-	-	-	-	-	(1)	1
Adjusted EBITA (Non-GAAP)¹	\$6,925	71.9%	\$2,299	\$880	\$615	\$3,812	\$3,113	\$6,221	71.0%	\$2,018	\$770	\$602	\$3,390	\$2,831

^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

Reconciliation of Reported Net Income (Loss) to EBITDA¹ and Adjusted EBITDA¹

mounts in millions USD	Three months e	nded December 31,	Twelve months er	nded December 31,
	2024	2023	2024	2023
Net Income (Loss)	\$98	(\$47)	(\$72)	(\$611)
Interest expense, net	328	356	1,355	1,302
Provision for income taxes	111	40	239	221
Depreciation and amortization	307	329	1,267	1,264
EBITDA	844	678	2,789	2,176
Adjustments:				
Goodwill impairments	-	91	-	493
Asset impairments	23	-	29	54
Restructuring, integration, and transformation costs	16	31	66	116
Acquisition related costs and adjustments (excluding amortization of intangible assets)	18	44	101	106
Gain on extinguishment of debt	-	(1)	(23)	(1)
Share-based compensation	43	29	150	132
Separation costs and separation-related costs	8	6	24	26
Other adjustments:				
Litigation and other matters, net of insurance recoveries	5	2	220	(53)
IT infrastructure investment	8	9	35	31
Legal and other professional fees	-	3	25	20
(Gain) loss on sale of assets, net	-	1	(10)	(3)
Other	7	4	19	13
Adjusted EBITDA (non-GAAP) ¹	972	897	3,425	3,110
Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) ¹	(37)	(28)	(118)	(96)
Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP) ¹	\$935	\$869	\$3,307	\$3,014
	Three months e	nded December 31,	Twelve months er	nded December 31,
	2024	2023	2024	2023

	Three months en	ded December 31,	Twelve months er	nded December 31,
	2024	2023	2024	2023
Net income attributable to noncontrolling interest	(\$5)	\$8	\$26	\$19
Noncontrolling interest portion of adjustments for:				
Interest expense, net	(11)	(11)	(46)	(32)
Depreciation and amortization	(13)	(13)	(51)	(42)
All other adjustments	(8)	(12)	(47)	(41)
Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) ¹	(\$37)	(\$28)	(\$118)	(\$96)

^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios

4Q24 Segment Profit² Reconciliation to Adjusted EBITDA¹

	Three	Months Ended Decembe	er 31, 2024	Three N	Months Ended December	· 31, 2023
	Revenue	Segment Profit ²	Segment Profit Margin	Revenue	Segment Profit ²	Segment Profit Margin
Salix	\$634	\$460	73%	\$583	\$419	72%
International	279	98	35%	290	99	34%
Solta Medical	138	73	53%	103	47	46%
Diversified Products	228	157	69%	259	169	65%
Total Bausch Health (excluding B+L)	\$1,279	\$788	62%	\$1,235	\$734	59%
Bausch + Lomb	1,280	309	24%	1,173	281	24%
Total	\$2,559	\$1,097	43%	\$2,408	\$1,015	42%
Corporate	-	(248)	-	-	(230)	-
Adjustments:						
Fair value inventory step-up resulting from acquisitions	-	21	-	-	21	-
IT infrastructure investment	-	8	-	-	9	-
Legal and other professional fees	-	-	-	-	3	-
Separation-related costs	-	7	-	-	5	-
Transformation Costs	-	10	-	-	10	-
Adjusted EBITA (non-GAAP) 1	-	\$895	-	-	\$833	-
Depreciation	-	48	-	-	47	-
Share-based compensation	-	43	-	-	29	-
Foreign exchange and other	-	(14)	-	-	(12)	-
Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) ¹	-	(37)	-	-	(28)	-
Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP) 1	-	\$935	-	-	\$869	-

^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

^{2.} Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation costs, Other (income) expense, net, and other corporate allocations are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.

FY24 Segment Profit² Reconciliation to Adjusted EBITDA¹

	Twelve	Months Ended December	er 31, 2024	Twelve I	Twelve Months Ended December		
	Revenue	Segment Profit ²	Segment Profit Margin	Revenue	Segment Profit ²	Segment Profit Margin	
Salix	\$2,333	\$1,602	69%	\$2,250	\$1,548	69%	
International	1,111	376	34%	1,071	335	31%	
Solta Medical	440	213	48%	347	161	46%	
Diversified Products	950	626	66%	943	586	62%	
Total Bausch Health (excluding B+L)	\$4,834	\$2,817	58%	\$4,611	\$2,630	57%	
Bausch + Lomb	4,791	1,108	23%	4,146	980	24%	
Total	\$9,625	\$3,925	41%	\$8,757	\$3,610	41%	
Corporate	-	(994)	-	-	(933)	-	
Adjustments:							
Fair value inventory step-up resulting from acquisitions	-	82	-	-	23	-	
IT infrastructure investment	-	35	-	-	31	-	
Legal and other professional fees	-	25	-	-	20	-	
Separation-related costs	-	21	-	-	22	-	
Transformation Costs	-	37	-	-	58	-	
Other expense	-	(18)	-	-	-	-	
Adjusted EBITA (non-GAAP) 1	-	\$3,113	-	-	\$2,831	-	
Depreciation	-	190	-	-	187	-	
Share-based compensation	-	150	-	-	132	-	
Foreign exchange and other	-	(28)	-	-	(40)	-	
Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) 1	-	(118)	-	-	(96)	-	
Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP) 1	-	\$3,307	-	-	\$3,014	-	

^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

^{2.} Segment profit is based on operating income after the elimination of intercompany transactions, including between Bausch + Lomb and other segments. Certain costs, such as Amortization of intangible assets, Asset impairments, Goodwill impairments, Restructuring, integration, separation costs, Other (income) expense, net, and other corporate allocations are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.

4Q24 Reconciliation of Reported Revenue to Organic Revenue^{1,2} and Organic Revenue Growth¹

Amounts in millions USD		For Three Months Ended						Change in		Change in		
		Deceml	ecember 31, 2024			December 31, 2023			Reported Revenue		Organic Revenue ¹	
	Revenue as reported	Changes in Exchange Rates ²	Acquisitions	Organic Revenue (Non-GAAP) ¹	Revenue as Reported	Divestitures and Discontinuations	Organic Revenue (Non-GAAP) ¹	Amount	Pct.	Amount	Pct.	
Salix	\$634	\$-	\$-	\$634	\$583	(\$19)	\$564	\$51	9%	\$70	12%	
International	279	10	-	289	290	(5)	285	(11)	(4%)	4	1%	
Solta Medical	138	1	-	139	103	-	103	35	34%	36	35%	
Neurology	142	-	-	142	141	-	141	1	1%	1	1%	
Dermatology	53	-	-	53	61	(6)	55	(8)	(13%)	(2)	(4%)	
Generics	9	-	-	9	28	2	30	(19)	(68%)	(21)	(70%)	
Dentistry	24	-	-	24	29	-	29	(5)	(17%)	(5)	(17%)	
Diversified	228	-	-	228	259	(4)	255	(31)	(12%)	(27)	(11%)	
Bausch Health (excl. B+L)	\$1,279	\$11	\$-	\$1,290	\$1,235	(\$28)	\$1,207	\$44	4%	\$83	7%	
Vision Care	723	12	-	735	662	(1)	661	61	9%	74	11%	
Surgical	231	3	(5)	229	204	-	204	27	13%	25	12%	
Pharmaceuticals	326	2	-	328	307	-	307	19	6%	21	7%	
Total Bausch + Lomb	\$1,280	\$17	(\$5)	\$1,292	\$1,173	(\$1)	\$1,172	\$107	9%	\$120	10%	
Total Bausch Health	\$2,559	\$28	(\$5)	\$2,582	\$2,408	(\$29)	\$2,379	\$151	6%	\$203	9%	

^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

^{2.} The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

FY24 Reconciliation of Reported Revenue to Organic Revenue^{1,2} and Organic Revenue Growth¹

Amounts in millions USD		For Twelve Months Ended						Change in		Change in	
		Decemb	per 31, 2024		December 31, 2023			Reported Revenue		Organic Revenue ¹	
	Revenue as reported	Changes in Exchange Rates ²	Acquisitions	Organic Revenue (Non-GAAP)¹	Revenue as Reported	Divestitures and Discontinuations	Organic Revenue (Non-GAAP)¹	Amount	Pct.	Amount	Pct.
Salix	\$2,333	\$-	\$-	\$2,333	\$2,250	(\$37)	\$2,213	\$83	4%	\$120	5%
International	1,111	(6)	-	1,105	1,071	(11)	1,060	40	4%	45	4%
Solta Medical	440	7	-	447	347	-	347	93	27%	100	29%
Neurology	543	-	-	543	494	-	494	49	10%	49	10%
Dermatology	238	-	-	238	226	(13)	213	12	5%	25	12%
Generics	74	-	-	74	120	(8)	112	(46)	(38%)	(38)	(34%)
Dentistry	95	-	-	95	103	-	103	(8)	(8%)	(8)	(8%)
Diversified	950	-	-	950	943	(21)	922	7	1%	28	3%
Bausch Health (excl. B+L)	\$4,834	\$1	\$-	\$4,835	\$4,611	(\$69)	\$4,542	\$223	5%	\$293	6%
Vision Care	2,739	54	(24)	2,769	2,543	(2)	2,541	196	8%	228	9%
Surgical	843	9	(9)	843	767	-	767	76	10%	76	10%
Pharmaceuticals	1,209	6	(260)	955	836	(6)	830	373	45%	125	15%
Total Bausch + Lomb	\$4,791	\$69	(\$293)	\$4,567	\$4,146	(\$8)	\$4,138	\$645	16%	\$429	10%
Total Bausch Health	\$9,625	\$70	(\$293)	\$9,402	\$8,757	(\$77)	\$8,680	\$868	10%	\$722	8%

^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

^{2.} The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

4Q24 & FY24 Reconciliation of Reported Cash Provided by Operating Activities to Adjusted Cash Flow from Operations (Non-GAAP)¹

Amounts in millions USD		nths Ended aber 31,	Twelve Months Ended December 31,		
	2024	2023	2024	2023	
Cash provided by operating activities	\$601	\$390	\$1,597	\$1,032	
Payments of legacy legal settlements, net of insurance proceeds	8	-	224	(79)	
Payments of transformation costs	12	17	34	68	
Payments of separation costs and separation-related costs	2	6	12	22	
Interest payments charged against premium	(22)	(108)	(295)	(282)	
Third party fees paid in connection with the Exchange	-	-	-	2	
Adjusted cash flow from operations (non-GAAP) ¹	\$601	\$305	\$1,572	\$763	

^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

4Q24 & FY24 Reconciliation of Reported Cash Provided by Operating Activities to Adjusted Cash Flow from Operations (Non-GAAP)¹

Amounts in millions USD		Ended 2024	Twelve Months Ended December 31, 2024			
	Bausch Health Companies Inc.	B+L	Bausch Health (excl. B+L) ²	Bausch Health Companies Inc.	B+L	Bausch Health (excl. B+L) ²
Cash provided by operating activities	\$601	\$22	\$577	\$1,597	\$232	\$1,364
Payments of legacy legal settlements, net of insurance proceeds	8	-	9	224	-	224
Payments of transformation costs	12	10	1	34	28	6
Payments of separation costs and separation-related costs	2	-	2	12	3	9
Interest payments charged against premium	(22)	-	(22)	(295)	-	(295)
Adjusted cash flow from operations (non-GAAP) ¹	\$601	\$32	\$567	\$1,572	\$263	\$1,308

^{1.} This is a non-GAAP measure. Management considers the presentation of Adjusted cash flow from operations for Bausch Health (excl. B+L) (non-GAAP) to be meaningful information and utilizes it in decision making and for compensation purposes. Adjusted cash flow from operations for Bausch Health (excl. B+L) (non-GAAP) is not intended to be representative of GAAP operating activities and Adjusted cash flow from operating activities for B+L is not intended to be representative of discontinued operations as the criteria for that accounting hasn't been met. As such, Adjusted cash flow from operations excluding B+L (non-GAAP) as included herein may not be indicative of the results of the operations or Adjusted cash flow from operations attributable to Bausch Health (non-GAAP) in the future, or if B+L met the criteria to be treated as a discontinued operation during any of the periods presented. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.

^{2.} Amounts may not cross foot due to rounding.

Trailing Twelve Months Adjusted EBITDA¹

	Trailing Twelve Months Ended							
	Dec-24	Sep-24	Jun-24	Mar-24	Dec-23			
Net Loss	(\$72)	(\$217)	(\$507)	(\$479)	(\$611)			
Interest expense, net	1,355	1,383	1,377	1,347	1,302			
Provision for income taxes	239	168	153	156	221			
Depreciation and amortization	1,267	1,289	1,268	1,265	1,264			
EBITDA	2,789	2,623	2,291	2,289	2,176			
Adjustments:								
Goodwill impairments	-	91	493	493	493			
Asset impairments	29	6	10	42	54			
Restructuring, integration and transformation costs	66	81	107	108	116			
Acquisition related costs and adjustments (excluding amortization of intangible assets)	101	127	124	93	106			
Gain on extinguishment of debt	(23)	(24)	(24)	(12)	(1)			
Share-based compensation	150	136	127	124	132			
Separation costs and separation-related costs	24	22	22	25	26			
Other adjustments:								
Litigation and other matters, net of insurance recoveries	220	217	53	(39)	(53)			
IT infrastructure investment	35	36	37	34	31			
Legal and other professional fees	25	28	21	23	20			
Gain on sale of assets, net	(10)	(9)	(9)	(7)	(3)			
Other	19	16	17	20	13			
Adjusted EBITDA (non-GAAP)¹	3,425	3,350	3,269	3,193	3,110			
Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) ¹	(118)	(109)	(107)	(102)	(96)			
Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP) ¹	\$3,307	\$3,241	\$3,162	\$3,091	\$3,014			

^{1.} This is a non-GAAP measure or non-GAAP ratio. See Slide 2 and Non-GAAP Appendix for further information on non-GAAP measures and ratios

Reconciliation of Reported Net Income (Loss) to Adjusted EBITDA¹

	Three Months Ended December 31, 2024			Three Months Ended December 31, 2023			
	Bausch Health Companies Inc.	Bausch + Lomb Corporation	Bausch Health (excl. B+L) ³	Bausch Health Companies Inc.	Bausch + Lomb Corporation	Bausch Health (excl. B+L) ³	
Net Income (Loss)	\$98	(\$2)	\$100	(\$47)	(\$56)	\$8	
Interest expense, net	328	93	235	356	96	261	
Provision for income taxes	111	(8)	119	40	(1)	41	
Depreciation and amortization	307	106	201	329	116	213	
EBITDA	844	189	655	678	155	523	
Adjustments:							
Goodwill impairments	-	-	-	91	-	91	
Asset impairments	23	-	23	-	-	-	
Restructuring, integration and transformation costs	16	14	2	31	20	11	
Acquisition related costs and adjustments (excluding amortization of intangible assets)	18	11	7	44	29	15	
Gain on extinguishment of debt	-	-	-	(1)	-	(1)	
Share-based compensation	43	27	16	29	16	13	
Separation costs and separation-related costs	8	6	2	6	3	3	
Other adjustments:							
Litigation and other matters	5	3	2	2	(2)	4	
IT infrastructure investment	8	8	-	9	7	2	
Legal and other professional fees	-	1	(1)	3	-	3	
Net (gain) loss on sale of assets	-	-	-	1	-	1	
Other	7	1	6	4	6	(2)	
Adjusted EBITDA (non-GAAP) ^{1,2}	\$972 ²	\$260 ²	\$712	\$8972	\$234 ²	\$663	

^{1.} This is a non-GAAP measure. Management considers the presentation of Adjusted EBITDA for Bausch Health (excl. B+L) (non-GAAP) to be meaningful information and utilizes it in decision making and for compensation purposes. Adjusted EBITDA for Bausch Health Excluding B+L (non-GAAP) is not intended to be representative of GAAP continuing operations and Adjusted EBITDA for B+L is not intended to be representative of discontinued operations as the criteria for that accounting hasn't been met. As such, Adjusted EBITDA excluding B+L (non-GAAP) as included herein may not be indicative of the results of the operations or Adjusted EBITDA attributable to Bausch Health (non-GAAP) in the future, or if B+L met the criteria to be treated as a discontinued operation during any of the periods presented. See Slide 2 and Non-GAAP Appendix for further information on this and other non-GAAP measures and ratios.

^{2.} Adjusted EBITDA (non-GAAP) above includes Adjusted EBITDA attributable to noncontrolling interests. For Bausch Health Companies Inc., this amounted to \$37 million and \$28 million for the three months ended December 31, 2024 and 2023, which includes \$1 million and \$3 million, respectively related to B+L.

^{3.} Amounts may not cross foot due to rounding.

Reconciliation of Reported Net (Loss) Income to Adjusted EBITDA¹

	Twelve Months Ended December 31, 2024			Twelve Months Ended December 31, 2023			
	Bausch Health Companies Inc.	Bausch + Lomb Corporation	Bausch Health (excl. B+L) ³	Bausch Health Companies Inc.	Bausch + Lomb Corporation	Bausch Health (excl. B+L) ³	
Net (Loss) Income	(\$72)	(\$305)	\$233	(\$611)	(\$253)	(\$362)	
Interest expense, net	1,355	384	971	1,302	268	1,034	
Provision for income taxes	239	71	168	221	87	134	
Depreciation and amortization	1,267	436	831	1,264	382	882	
EBITDA	2,789	586	2,203	2,176	484	1,688	
Adjustments:							
Goodwill impairments	-	-	-	493	-	493	
Asset impairments	29	5	24	54	-	54	
Restructuring, integration and transformation costs	66	56	10	116	97	19	
Acquisition related costs and adjustments (excluding amortization of intangible assets)	101	77	24	106	50	56	
Gain on extinguishment of debt	(23)	-	(23)	(1)	-	(1)	
Share-based compensation	150	92	58	132	74	58	
Separation costs and separation-related costs	24	12	12	26	10	16	
Other adjustments:							
Litigation and other matters	220	5	215	(53)	-	(53)	
IT infrastructure investment	35	35	-	31	26	5	
Legal and other professional fees	25	6	19	20	-	20	
Net (gain) loss on sale of assets	(10)	(5)	(5)	(3)	-	(3)	
Other	19	3	16	13	9	4	
Adjusted EBITDA (non-GAAP) ^{1,2}	\$3,425 ²	\$872 ²	\$2,553	\$3,110 ²	\$750 ²	\$2,356	

^{1.} This is a non-GAAP measure. Management considers the presentation of Adjusted EBITDA for Bausch Health (excl. B+L) (non-GAAP) to be meaningful information and utilizes it in decision making and for compensation purposes. Adjusted EBITDA for Bausch Health Excluding B+L (non-GAAP) is not intended to be representative of GAAP continuing operations and Adjusted EBITDA for B+L is not intended to be representative of discontinued operations as the criteria for that accounting hasn't been met. As such, Adjusted EBITDA excluding B+L (non-GAAP) as included herein may not be indicative of the results of the operations or Adjusted EBITDA attributable to Bausch Health (non-GAAP) in the future, or if B+L met the criteria to be treated as a discontinued operation during any of the periods presented. See Slide 3 and Non-GAAP Appendix for further information on this and other non-GAAP measures and ratios.

^{2.} Adjusted EBITDA (non-GAAP) above includes Adjusted EBITDA attributable to noncontrolling interests. For Bausch Health Companies Inc., this amounted to \$118 million and \$96 million for the twelve months ended December 31, 2024 and 2023, which includes \$12 million and \$12 million, respectively related to B+L.

^{3.} Amounts may not cross foot due to rounding.

Description of Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with U.S. GAAP, the Company uses certain non-GAAP financial measures and non-GAAP ratios. These measures and ratios do not have any standardized meaning under GAAP and other companies may use similarly titled non-GAAP financial measures and ratios that are calculated differently from the way we calculate such measures and ratios. Accordingly, our non-GAAP financial measures and ratios may not be comparable to such similarly titled non-GAAP financial measures and ratios used by other companies. We caution investors not to place undue reliance on such non-GAAP measures, but instead to consider them with the most directly comparable GAAP measures and ratios. Non-GAAP financial measures and ratios have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

Adjusted EBITDA and Adjusted EBITDA Attributable to Bausch Health

Adjusted EBITDA (non-GAAP) is Net income (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (Benefit from) provision for income taxes, depreciation and amortization and certain other items described below. Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) as defined below.

Management believes that Adjusted EBITDA (non-GAAP) and Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP), along with the GAAP measures used by management, most appropriately reflect how the Company measures the business internally and sets operational goals and incentives. In particular, the Company believes that these metrics focus management on the Company's underlying operational results and business performance. As a result, the Company uses these metrics to assess the financial performance of the Company and to forecast future results as part of its guidance. Management believes these metrics are a useful measure to evaluate current performance. These metrics are intended to show our unleveraged, pre-tax operating results and therefore reflect our financial performance based on operational factors. In addition, cash bonuses for the Company's executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) targets.

Adjusted EBITDA (non-GAAP) is Net income (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (Benefit from) provision for income taxes, depreciation and amortization and the following items:

Restructuring, integration and transformation costs: The Company has incurred restructuring costs as it implemented certain strategies, which involved, among other things, improvements to its infrastructure and operations, internal reorganizations and impacts from the divestiture of assets and businesses. With regard to infrastructure and operational improvements which the Company has taken to improve efficiencies in the businesses and facilities, these tend to be costs intended to right size the business or organization that fluctuate significantly between periods in amount, size and timing, depending on the improvement project, reorganization or transaction. Additionally, with the completion of the B+L IPO, as the Company prepares for post-separation operations, the Company is launching certain transformation initiatives that will result in certain changes to and investment in its organizational structure and operations. These transformation initiatives arise outside of the ordinary course of continuing operations and, as is the case with the Company's restructuring efforts, costs associated with these transformation initiatives are expected to fluctuate between periods in amount, size and timing. These out-of-the-ordinary-course charges include third-party advisory costs, as well as certain severance-related costs

(including the severance costs associated with the departure of Bausch + Lomb's former CEO). Investors should understand that the outcome of these transformation initiatives may result in future restructuring actions and certain of these charges could recur. The Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

- Asset Impairments: The Company has excluded the impact of impairments of finite-lived and indefinite-lived intangible assets, as well as impairments of assets held for sale, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions and divestitures. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes impairments of intangible assets and assets held for sale from measuring the performance of the Company and the business, the Company believes that it is important for investors to understand that intangible assets contribute to revenue generation.
- Goodwill Impairments: The Company excludes the impact of goodwill impairments. When the Company has made acquisitions where the consideration paid was in excess of the fair value of the net assets acquired, the remaining purchase price is recorded as goodwill. For assets that we developed ourselves, no goodwill is recorded. Goodwill is not amortized but is tested for impairment. The amount of goodwill impairment is measured as the excess of a reporting unit's carrying value over its fair value. Management excludes these charges in measuring the performance of the Company and the business.
- Share-based compensation: The Company has excluded costs relating to share-based compensation. The Company believes that the exclusion of share-based compensation expense assists investors in the comparisons of operating results to peer companies. Share-based compensation expense can vary significantly based on the timing, size and nature of awards granted.
- Acquisition-related costs and adjustments excluding amortization of intangible assets: The Company has excluded the impact of acquisition-related costs and fair value inventory step-up resulting from acquisitions as the amounts and frequency of such costs and adjustments are not consistent and are significantly impacted by the timing and size of its acquisitions. In addition, the company excludes acquisition-related contingent consideration non-cash adjustments due to the inherent uncertainty and volatility associated with such amounts based on changes in assumptions with respect to fair value estimates, and the amount and frequency of such adjustments are not consistent and are significantly impacted by the timing and size of the Company's acquisitions, as well as the nature of the agreed-upon consideration.
- Gain (Loss) on extinguishment of debt: The Company has excluded gain (loss) on extinguishment of debt as this
 represents a gain or loss from refinancing our existing debt and is not a reflection of our operations for the period. Further,
 the amount and frequency of such amounts are not consistent and are significantly impacted by the timing and size of debt
 financing transactions and other factors in the debt market out of management's control.

- Separation costs and separation-related costs: The Company has excluded certain costs incurred in connection with activities regarding the separation of the eye-health business. Separation costs are incremental costs directly related to effectuating the separation of the eye-health business and include, but are not limited to, legal, audit and advisory fees. Separation-related costs are incremental costs indirectly related to the separation of the eye-health business and include, but are not limited to rebranding costs and costs associated with facility relocation and/or modification. As these costs arise from events outside of the ordinary course of continuing operations, the Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.
- Other adjustments: The Company has excluded certain other amounts, including legal and other professional fees incurred in connection with legal and governmental proceedings, investigations and information requests regarding certain of our legacy distribution, marketing, pricing, disclosure and accounting practices, litigation and other matters, and net (gain) loss on sale of assets or other disposition of assets. Given the unique nature of the matters relating to these costs, the Company believes these items are not normal operating expenses. For example, legal settlements and judgments vary significantly, in their nature, size and frequency, and, due to this volatility, the Company believes the costs associated with legal settlements and judgments are not normal operating expenses. In addition, as opposed to more ordinary course matters, the Company considers that each of the recent proceedings, investigations and information requests, given their nature and frequency, are outside of the ordinary course and relate to unique circumstances. The Company has also excluded IT infrastructure investments that are the result of other, non-comparable events to measure operating performance. These events arise outside of the ordinary course of continuing operations. The Company has also excluded certain other costs, including professional fees associated with contemplated, but not completed, strategic transactions. The Company excluded these costs as the consideration of such matters are outside of the ordinary course of continuing operations and are infrequent in nature. The Company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the Company from period to period and, therefore, provides useful supplemental information to investors. However, investors should understand that many of these costs could recur and that companies in our industry often face litigation.

Adjusted EBITDA attributable to Bausch Health (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to noncontrolling interest (non-GAAP). Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) is Net income attributable to noncontrolling interest (its most directly comparable GAAP financial measure) adjusted for the portion of the adjustments described above attributable to noncontrolling interest.

Adjusted Net Income and Adjusted Net Income attributable to Bausch Health

Adjusted net income (non-GAAP) is Net income (its most directly comparable GAAP financial measure), adjusted for asset impairments, goodwill impairments, restructuring, integration and transformation costs, acquisition-related costs and adjustments excluding amortization of intangible assets, gain (loss) on extinguishment of debt, separation costs and separation-related costs and other non-GAAP adjustments as these adjustments are described above, and amortization of intangible assets and acquisition-related costs and adjustments excluding amortization of intangible

assets, as described below:

- Amortization of intangible assets: The Company has excluded the impact of amortization of intangible assets, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes the amortization of intangible assets from its non-GAAP expenses, the Company believes that it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in the amortization of additional intangible assets.
- Acquisition-related costs and adjustments excluding amortization of intangible assets: In addition to the acquisition-related costs and adjustments as described above, the company has excluded the expense directly attributable to one-time commitment and structuring fees related to a bridge loan facility put in place prior to the acquisition of Xiidra and certain other ophthalmology assets. The company excluded these costs as they are outside of the ordinary course of continuing operations and are infrequent in nature. The company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the company from period to period and, therefore, provides useful supplemental information to investors.

Adjusted net income attributable to Bausch Health (non-GAAP) is Adjusted net income (non-GAAP) further adjusted to exclude the Adjusted net income attributable to noncontrolling interest (non-GAAP). Adjusted net income attributable to noncontrolling interest (non-GAAP) is Net income attributable to noncontrolling interest (its most directly comparable GAAP financial measure) adjusted for the portion of the adjustments described above attributable to noncontrolling interest.

Historically, management has used Adjusted net income (loss) (non-GAAP) for strategic decision making, forecasting future results and evaluating current performance. This non-GAAP measure excludes the impact of certain items (as described above) that may obscure trends in the Company's underlying performance. By disclosing this non-GAAP measure, it is management's intention to provide investors with a meaningful, supplemental comparison of the Company's operating results and trends for the periods presented. Management believes that this measure is also useful to investors as such measure allows investors to evaluate the Company's performance using the same tools that management uses to evaluate past performance and prospects for future performance. Accordingly, the Company believes that Adjusted net income (non-GAAP) is useful to investors in their assessment of the Company's operating performance. It is also noted that, in recent periods, our GAAP Net income (loss) was significantly lower than our Adjusted net income (non-GAAP).

Organic Growth/Change and Organic Revenue

Organic revenue and organic revenue change are non-GAAP measures. Non-GAAP measures are not standardized measures under the financial reporting framework used to prepare the Company's financial statements and might not be comparable to similar financial measures disclosed by other issuers.

Organic revenue and change in organic revenue (non-GAAP), are defined as GAAP Revenue and changes in GAAP revenue (the most directly comparable GAAP financial measures), adjusted for changes in foreign currency exchange rates (if applicable) and excluding the impact of recent acquisitions, divestitures and discontinuations, as defined further below. Organic revenue (non-GAAP) is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue (non-GAAP) and change in organic revenue (non-GAAP) to assess performance of its reportable segments and the Company in total. The Company believes that providing these non-GAAP measures is useful to investors as they provide a supplemental period-to-period comparison.

The adjustments to GAAP Revenue to determine Organic Revenue (non-GAAP) and changes in Organic Revenue (non-GAAP) are as follows:

• Foreign currency exchange rates: Although changes in foreign currency exchange rates are part of our business, they are not within management's control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the business. The impact of changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

• Acquisitions, divestitures and discontinuations: In order to present period-over-period organic revenue (non-GAAP) growth/change on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue and change in organic revenue exclude from the current period, revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue and change in organic revenue exclude from the prior period, all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period.

Adjusted EBITA and Adjusted EBITA Margin

Adjusted EBITA represents Operating income (loss) (its most directly comparable GAAP financial measure) adjusted to exclude amortization, fair value adjustments to inventory in connection with business combinations and integration related inventory charges and technology transfer costs, restructuring and integration costs, asset impairments, goodwill impairments, acquisition related costs, separation costs, separation-related costs and certain other non-GAAP charges as discussed under "Other Non-GAAP charges" above. Adjusted EBITA Margin (non-GAAP) is Adjusted EBITA (non-GAAP) divided by Revenues. The most directly comparable GAAP financial measure is operating income margin, which is Operating income (loss) divided by Revenues. On a segment basis, Adjusted EBITA represents Segment profit (its most directly comparable GAAP financial measure) adjusted to exclude the items above, as applicable.

Management believes that Adjusted EBITA (non-GAAP) and Adjusted EBITA Margin (non-GAAP), along with the GAAP measures used by management, appropriately reflect how the Company measures the business internally and sets operational goals for each of its businesses. In particular, the Company believes that Adjusted EBITA (non-GAAP) and Adjusted EBITA Margin (non-GAAP) focuses management on the Company's underlying operational results and segment performance. As a result, the Company uses Adjusted EBITA (non-GAAP) and Adjusted EBITA Margin (non-GAAP) to assess the actual financial performance of each segment and to forecast future results as part of its guidance.

The Company believes that Adjusted EBITA (non-GAAP) and Adjusted EBITA Margin (non-GAAP) are useful to investors as they provide consistency and comparability with our past financial performance and facilitates period-to-period comparisons of the Company's profitability and the profitability of our segments as they eliminate the effects of certain cash and non-cash charges, which given their nature and frequency, are outside the ordinary course and relate to unique circumstances.

Adjusted Gross Profit and Adjusted Gross Margin

Adjusted gross profit (non-GAAP) represents gross profit (its most directly comparable GAAP financial measure) adjusted for Other revenues, Cost of other revenues, Amortization of intangible assets and fair value adjustments to inventory in connection with business combinations. In accordance with GAAP, Gross profit represents total Revenues less Costs of goods sold (excluding amortization of intangible assets) less Cost of other revenues less Amortization of intangible assets. Adjusted gross margin (non-GAAP) (the most directly comparable GAAP financial measure for which is gross margin) represents Adjusted gross profit (non-GAAP) divided by Product revenues.

Adjusted gross profit (non-GAAP) and Adjusted gross margin (non-GAAP) are measures used by management to understand and evaluate each segment's pricing strategy, strength of product portfolio, ability to control product costs and the success of its go-to-market strategies. Adjusted gross profit (non-GAAP) and Adjusted gross margin (non-GAAP) facilitates period-to-period comparisons of each segment's ability to generate cash flow from sales, as these measures eliminate the effects of amortization of intangible assets and fair value adjustments to inventory in connection with business combinations, which are non-cash charges.

The Company believes that Adjusted gross profit (non-GAAP) and Adjusted gross margin (non-GAAP) are useful to investors as they provide consistency and comparability with our past financial performance and facilitate period-to-period comparisons of each segment's ability to generate incremental cash flow from its revenues as these measures eliminate the effects of amortization of intangible assets and fair value adjustments to inventory in connection with business combinations, which are non-cash charges that can be impacted by, among other things, the timing and magnitude of acquisitions, which given their nature and frequency, are outside the ordinary course and relate to unique circumstances.

Adjusted SG&A Expenses and Adjusted G&A Expenses

Adjusted SG&A expenses (non-GAAP) represents selling, general and administrative expenses ("SG&A expenses") (its most directly comparable GAAP financial measure) and Adjusted G&A expenses (non-GAAP) represents general and administrative expenses ("G&A expenses") (its most directly comparable GAAP financial measure), each adjusted to exclude separation-related costs and certain costs primarily related to legal and other professional fees relating to legal and governmental proceedings, investigations and information requests respecting certain of our distribution, marketing, pricing, disclosure and accounting practices and separation-related costs. See the discussion under "Other Non-GAAP charges" above.

Management uses Adjusted SG&A expenses (non-GAAP) and Adjusted G&A (non-GAAP), along with GAAP measures, as a supplemental measure for period-to-period comparison to understand and evaluate each segment's ability to control costs and direct additional cash investments in each business.

provide consistency and comparability with our past financial performance and facilitates period-to-period comparisons of our SG&A expenses, G&A expenses and operations, as these measures eliminate the effects of separation-related costs and legal and other professional fees which given their nature and frequency, are outside the ordinary course and relate to unique circumstances.

Total Adjusted Operating Expenses

Total Adjusted Operating Expenses (non-GAAP) represents operating expenses (its most directly comparable GAAP financial measure) adjusted to exclude restructuring and integration costs, asset impairments, including loss on assets held for sale, goodwill impairments, acquisition related costs and adjustments excluding amortization of intangible assets, separation costs, separation-related costs and certain other non-GAAP charges as discussed under "Other Non-GAAP charges" above.

Management believes that Total Adjusted Operating Expenses (non-GAAP), along with the GAAP and non-GAAP measures used by management, provide a supplemental measure for period-to-period comparison to understand and evaluate its ability manage and control its costs, assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes that Total Adjusted Operating Expenses (non-GAAP) is a useful measure to evaluate current performance amounts.

The Company believes that Total Adjusted Operating Expenses (non-GAAP) is useful to investors as it provides consistency and comparability with our past financial performance and facilitates period-to-period comparisons of our operating expenses as Total Adjusted Operating Expenses eliminates the effects of certain cash and non-cash charges, which given their nature and frequency, are outside the ordinary course and relate to unique circumstances which are substantially outside of management's control.

Adjusted Cash Flow from Operations

Adjusted cash flow from operations (non-GAAP) is Cash generated from operations (its most directly comparable GAAP financial measure) adjusted for: (i) payments of legacy legal settlements, net of insurance proceeds, (ii) payments of transformation costs, (iii) payments for separation costs and separation-related costs, (iv) interest payments charged against premium, and (v) fees paid in connection with the debt exchange transaction

Management believes that Adjusted cash flow from operations (non-GAAP), along with the GAAP and non-GAAP measures used by management, most appropriately reflect how the Company measures the business internally. The Company uses adjusted cash flow from operations (non-GAAP) both to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes adjusted cash flow from operations (non-GAAP) is a useful measure to evaluate current performance amounts.

As these payments arise from events outside of the ordinary course of continuing operations as discussed above, the Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's cash from operations, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors.

Constant Currency

Changes in the relative values of non-U.S. currencies to the U.S. dollar may affect the Company's financial results and financial position. To assist investors in evaluating the Company's performance, we have adjusted for the effects of changes in foreign currencies. The impact of changes in foreign currency exchange rates is determined by comparing the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.

Adjusted Tax Rate

Adjusted Tax Rate (the most directly comparable financial measure for which is our GAAP tax rate) includes the tax impact of the various non-GAAP adjustments used in calculating our non-GAAP measures. However, due to the differences in the tax treatment of items excluded from non-GAAP earnings, our adjusted tax rate will differ from our GAAP tax rate and from our actual tax liabilities.

Adjusted EBITDA excluding Bausch + Lomb (non-GAAP)

Adjusted EBITDA excluding Bausch + Lomb (non-GAAP) is Adjusted EBITDA (non-GAAP) adjusted to remove Adjusted EBITDA attributable to Bausch + Lomb (non-GAAP). Adjusted EBITDA attributable to Bausch + Lomb (non-GAAP) is Income (loss) before income taxes of our Bausch + Lomb segment (its most directly comparable GAAP financial measure) adjusted for the portion of the Company's interest expense, depreciation, amortization and other adjustments as described above, allocated or attributable to Bausch + Lomb.

Adjusted EBITDA excluding Bausch + Lomb is not intended to be, and may not be, representative of income from continuing operations (for Bausch Health excluding Bausch + Lomb) or from discontinued operations (for B+L) in accordance with GAAP, as: (i) the criteria for that accounting has not been met and (ii) certain cost allocations to BHC excluding B+L and B+L are not in accordance with the criteria for that accounting. As such, Adjusted EBITDA excluding Bausch + Lomb (non-GAAP) as included herein may not be indicative of the results of the operations or Adjusted EBITDA attributable to Bausch Health (non-GAAP) in the future, or if Bausch + Lomb met the criteria to be treated as a discontinued operation during any of the periods presented.

Adjusted Cash Flow from Operations excluding Bausch + Lomb (non-GAAP)

Adjusted Cash Flow from Operations excluding Bausch + Lomb (non-GAAP) is Adjusted Cash Flow from Operations (non-GAAP) adjusted to remove Adjusted Cash Flow from Operations attributable to Bausch + Lomb (non-GAAP). Adjusted Cash Flow from Operations attributable to Bausch + Lomb (non-GAAP) is Cash Flow from Operations of our Bausch + Lomb segment (its most directly comparable GAAP financial measure) adjusted for the portion of the Company's payment of separation costs, separation-related costs and other adjustments as described above, allocated or attributable to Bausch + Lomb.

Adjusted Cash Flow from Operations excluding Bausch + Lomb is not intended to be, and may not be, representative of Cash Flow from Operations (for Bausch Health excluding Bausch + Lomb) or from discontinued operations (for B+L) in accordance with GAAP, as: (i) the criteria for that accounting has not been met and (ii) certain cost allocations to BHC excluding B+L and B+L are not in accordance with the criteria for that accounting. As such, Adjusted Cash Flow from Operations excluding Bausch + Lomb (non-GAAP) as included herein may not be indicative of the cash flow or Adjusted Cash Flow from Operations attributable to Bausch Health (non-GAAP) in the future, or if Bausch + Lomb met the criteria to be treated as a discontinued operation during any of the periods presented.

Management believes that Adjusted EBITDA excluding Bausch + Lomb (non-GAAP) and Adjusted Cash Flow from Operations excluding Bausch + Lomb (non-GAAP), along with the GAAP and other non-GAAP measures used by management, most appropriately reflects how the Company measures the business internally and sets operational goals and incentives. In particular, the Company believes that these metrics focus management on the Company's underlying operational results and business performance. As a result, the Company uses these metrics to assess the actual financial performance of the Company and to forecast future results as part of its guidance. Management believes these metrics are a useful measure to evaluate current performance. These metrics are intended to show our unleveraged, pre-tax operating results and therefore reflects our financial performance based on operational factors. In addition, cash bonuses for the Company's executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) and Adjusted Cash Flow (non-GAAP) targets.